Literature DB >> 28900819

A homozygous PIGO mutation associated with severe infantile epileptic encephalopathy and corpus callosum hypoplasia, but normal alkaline phosphatase levels.

Yoav Zehavi1, Anja von Renesse2, Etty Daniel-Spiegel3,4, Yonatan Sapir5, Luci Zalman6, Ilana Chervinsky7, Markus Schuelke2, Rachel Straussberg8, Ronen Spiegel9,10.   

Abstract

We describe two sisters from a consanguineous Arab family with global developmental delay, dystrophy, axial hypotonia, epileptic encephalopathy dominated by intractable complex partial seizures that were resistant to various anti-epileptic treatments. Dysmorphic features comprised low set ears, hypertelorism, upslanting palpebral fissures, a broad nasal bridge, and blue sclera with elongated eyelashes. Brain MRI in both children showed a corpus callosum hypoplasia that was evident already in utero and evolving cortical atrophy. Autozygosity mapping in combination with Whole Exome Sequencing revealed a homozygous missense mutation in the PIGO gene [c.765G > A, NM_032634.3] that affected a highly conserved methionine in the alkaline phosphatase-like core domain of the protein [p.(Met255Ile), NP_116023.2]. PIGO encodes the GPI-ethanolamine phosphate transferase 3, which is crucial for the final synthetic step of the glycosylphosphatidylinositol-anchor that attaches many enzymes to their cell surfaces, such as the alkaline phosphatase and granulocyte surface markers. Interestingly, measurement of serum alkaline phosphatase activities in both children was normal or only slightly elevated. Quantification of granulocyte surface antigens CD16/24/59 yielded reduced levels only for CD59. Phenotype analysis of our and other published patients with PIGO mutations reveals a more severe affectation and predominantly neurological presentation in individuals carrying a mutation in the alkaline phosphatase-like core domain thereby hinting towards a genotype-phenotype relation for PIGO gene mutations.

Entities:  

Keywords:  Autozygosity mapping; Epileptic encephalopathy; Exome sequencing; PIGO gene

Mesh:

Substances:

Year:  2017        PMID: 28900819     DOI: 10.1007/s11011-017-0109-y

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  14 in total

1.  Neurology of inherited glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

2.  Multiple congenital anomalies-hypotonia-seizures syndrome is caused by a mutation in PIGN.

Authors:  Gal Maydan; Iris Noyman; Adi Har-Zahav; Ziva Ben Neriah; Metsada Pasmanik-Chor; Adva Yeheskel; Adi Albin-Kaplanski; Idit Maya; Nurit Magal; Efrat Birk; Amos J Simon; Ayelet Halevy; Gideon Rechavi; Mordechai Shohat; Rachel Straussberg; Lina Basel-Vanagaite
Journal:  J Med Genet       Date:  2011-04-14       Impact factor: 6.318

3.  Vitamin B6-responsive epilepsy due to inherited GPI deficiency.

Authors:  Ichiro Kuki; Yukitoshi Takahashi; Shin Okazaki; Hisashi Kawawaki; Eiji Ehara; Norimitsu Inoue; Taroh Kinoshita; Yoshiko Murakami
Journal:  Neurology       Date:  2013-09-18       Impact factor: 9.910

4.  Mutations in the glycosylphosphatidylinositol gene PIGL cause CHIME syndrome.

Authors:  Bobby G Ng; Karl Hackmann; Melanie A Jones; Alexey M Eroshkin; Ping He; Roy Wiliams; Shruti Bhide; Vincent Cantagrel; Joseph G Gleeson; Amy S Paller; Rhonda E Schnur; Sigrid Tinschert; Janice Zunich; Madhuri R Hegde; Hudson H Freeze
Journal:  Am J Hum Genet       Date:  2012-03-22       Impact factor: 11.025

5.  Hyperphosphatasia-mental retardation syndrome due to PIGV mutations: expanded clinical spectrum.

Authors:  Denise Horn; Peter Krawitz; Anca Mannhardt; Georg Christoph Korenke; Peter Meinecke
Journal:  Am J Med Genet A       Date:  2011-07-07       Impact factor: 2.802

6.  MutationTaster2: mutation prediction for the deep-sequencing age.

Authors:  Jana Marie Schwarz; David N Cooper; Markus Schuelke; Dominik Seelow
Journal:  Nat Methods       Date:  2014-04       Impact factor: 28.547

7.  PIGO mutations in intractable epilepsy and severe developmental delay with mild elevation of alkaline phosphatase levels.

Authors:  Kazuyuki Nakamura; Hitoshi Osaka; Yoshiko Murakami; Rie Anzai; Kiyomi Nishiyama; Hirofumi Kodera; Mitsuko Nakashima; Yoshinori Tsurusaki; Noriko Miyake; Taroh Kinoshita; Naomichi Matsumoto; Hirotomo Saitsu
Journal:  Epilepsia       Date:  2014-01-13       Impact factor: 5.864

8.  Mutations in PIGO, a member of the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation.

Authors:  Peter M Krawitz; Yoshiko Murakami; Jochen Hecht; Ulrike Krüger; Susan E Holder; Geert R Mortier; Barbara Delle Chiaie; Elfride De Baere; Miles D Thompson; Tony Roscioli; Szymon Kielbasa; Taroh Kinoshita; Stefan Mundlos; Peter N Robinson; Denise Horn
Journal:  Am J Hum Genet       Date:  2012-06-07       Impact factor: 11.025

9.  Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency.

Authors:  Antonio M Almeida; Yoshiko Murakami; D Mark Layton; Peter Hillmen; Gabrielle S Sellick; Yusuke Maeda; Stephen Richards; Scott Patterson; Ioannis Kotsianidis; Luigina Mollica; Dorothy H Crawford; Alastair Baker; Michael Ferguson; Irene Roberts; Richard Houlston; Taroh Kinoshita; Anastasios Karadimitris
Journal:  Nat Med       Date:  2006-06-11       Impact factor: 53.440

Review 10.  Biosynthesis, remodelling and functions of mammalian GPI-anchored proteins: recent progress.

Authors:  Taroh Kinoshita; Morihisa Fujita; Yusuke Maeda
Journal:  J Biochem       Date:  2008-07-17       Impact factor: 3.387

View more
  4 in total

1.  Establishment of mouse model of inherited PIGO deficiency and therapeutic potential of AAV-based gene therapy.

Authors:  Ryoko Kuwayama; Keiichiro Suzuki; Jun Nakamura; Emi Aizawa; Yoshichika Yoshioka; Masahito Ikawa; Shin Nabatame; Ken-Ichi Inoue; Yoshiari Shimmyo; Keiichi Ozono; Taroh Kinoshita; Yoshiko Murakami
Journal:  Nat Commun       Date:  2022-06-03       Impact factor: 17.694

2.  Characterization of glycosylphosphatidylinositol biosynthesis defects by clinical features, flow cytometry, and automated image analysis.

Authors:  Alexej Knaus; Jean Tori Pantel; Manuela Pendziwiat; Nurulhuda Hajjir; Max Zhao; Tzung-Chien Hsieh; Max Schubach; Yaron Gurovich; Nicole Fleischer; Marten Jäger; Sebastian Köhler; Hiltrud Muhle; Christian Korff; Rikke S Møller; Allan Bayat; Patrick Calvas; Nicolas Chassaing; Hannah Warren; Steven Skinner; Raymond Louie; Christina Evers; Marc Bohn; Hans-Jürgen Christen; Myrthe van den Born; Ewa Obersztyn; Agnieszka Charzewska; Milda Endziniene; Fanny Kortüm; Natasha Brown; Peter N Robinson; Helenius J Schelhaas; Yvonne Weber; Ingo Helbig; Stefan Mundlos; Denise Horn; Peter M Krawitz
Journal:  Genome Med       Date:  2018-01-09       Impact factor: 11.117

3.  A novel PGAP3 mutation in a Croatian boy with brachytelephalangy and a thin corpus callosum.

Authors:  Tomohiro Sakaguchi; Tamara Žigman; Danijela Petković Ramadža; Lana Omerza; Silvija Pušeljić; Zrinka Ereš Hrvaćanin; Noriko Miyake; Naomichi Matsumoto; Ivo Barić
Journal:  Hum Genome Var       Date:  2018-03-08

Review 4.  The Glycosylphosphatidylinositol biosynthesis pathway in human diseases.

Authors:  Tenghui Wu; Fei Yin; Shiqi Guang; Fang He; Li Yang; Jing Peng
Journal:  Orphanet J Rare Dis       Date:  2020-05-28       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.